SBI Life Insurance (SBILIF)



CMP: ₹ 1214

Target: ₹ 1400 (15%) Targ

Target Period: 12 months

January 24, 2022

Healthy premium growth; outlook optimistic...

About the stock: SBI Life (SBIL) is among most dominant players in the Indian life insurance industry with strong distribution network, parentage, operating metrics.

- Balanced product mix with focus on opex ratio ahead of industry
- Strong parentage led distribution remains key catalyst

Q3FY22 Results: Healthy business traction, outlook optimistic.

- Gross premium growth healthy at 31% YoY; NBP growth at 56% YoY
- VNB margins healthy at 21.9%, aided by product mix and rise in pricing
- PAT at ₹ 236 crore, aided by healthy premium accretion
- Net Covid claim at ₹ 1530 crore for 9MFY22; Covid reserve at ₹ 270 crore

What should investors do? SBIL's share price has grown by ~1.7x over the past four years (from $\sim \stackrel{\scriptstyle <}{\scriptstyle <} 700$ in October 2017 to $\sim \stackrel{\scriptstyle <}{\scriptstyle <} 1214$ levels in January 2022).

• Factoring in distribution strength & diversified product mix, we retain our BUY rating on the stock

Target Price & Valuation: We value SBIL at 2.8x FY24 EV with revised TP of ₹ 1400.

Key triggers for future price performance:

- Launch of non-par & protection product to aid overall growth and VNB
- Product mix & improvement in persistency to aid VNB margins at 21-22%
- Covid claim seen to moderate; reserves at ₹ 270 crore seem comfortable
- Strong distribution network remains core to maintain business momentum

Alternate Stock Idea: Apart from SBIL, in our coverage we also like HDFC Life.

- Dominant player in life insurance industry with huge growth potential coupled with strong distribution, product suite and best VNB margin
- BUY with a target price of ₹ 800



BUY

Particulars	
Particulars	Amount
Market Capitalisation	₹ 123810 crore
EV (02FY22)	₹ 35290 crore
AUM (Q3FY22)	₹ 256870 crore
52 week H/L	1293/838
Face value	₹10

Sharehold	Shareholding pattern										
	Dec20	Mar21	Jun21	Sep21	Dec21						
Promoter	60.7	55.7	55.7	55.7	55.7						
FII	25.8	30.5	27.2	24.5	24.5						
DII	7.1	7.0	12.4	12.1	12.0						
Others	6.5	6.9	4.7	7.8	7.8						

Price Chart



Risk to our call

- Healthy pick-up in NBP in Q3FY22. Moderation in Covid claims
- Key Risk: 1) Increasing competitive intensity; 2) higher claim from group plan can impact surplus

Research Analyst

Kajal Gandhi kajal.gandhi@icicisecurities.com

Vishal Narnolia vishal.narnolia@icicisecurities.com

Sameer Sawant Sameer.sawant@icicisecurities.com

Dixit Sankharva dixit.sankharva@icicisecurities.com

Key Financial Summary								
(₹ Crore)	FY19	FY20	FY21	3 year CAGR (FY18-FY21)	FY22E	FY23E	FY24E	3 year CAGR (FY22-24E)
New business premium	14855.4	18071.4	20620.0	19%	24501.2	28295.8	32693.1	17%
APE	9530.7	10505.2	11450.0	15%	13423.1	15622.1	18188.9	17%
Total premium	32745.5	40334.4	49769.2	24%	58692.5	67889.6	78628.9	16%
PAT	1335.8	1423.0	1460.0	11%	892.3	1397.5	1931.0	10%
EV	22077.6	26290.0	33390.0	19%	36678.7	43219.2	50811.8	15%
P/E (x)	92.6	86.9	85.0		138.6	88.5	64.1	
P/BV (x)	14.1	12.5	11.9		11.4	10.4	9.2	
P/IEV (x)	5.6	4.7	4.0		3.4	2.9	2.4	
RoEV (%)	17.8	17.5	16.9		17.3	17.7	18.1	

Key takeaways of recent quarter & conference call highlights

Q3FY22 Results: Healthy performance; Covid claims moderate

- Premium growth healthy at 31% YoY to ₹ 18025 crore, led by 56.3% YoY traction in NBP ₹ 8503 crore and ~14.4% YoY growth in renewals to ₹ 9653 crore
- For 9MFY22, healthy traction in individual business at 43% YoY to ₹ 11610 crore, primarily led by rise in unit linked business
- Protection business (individual + group) continued to report strong growth at 26% YoY to ₹ 2040 crore. Proportion of total protection NBP to total NBP was at ~11% in 9MFY22
- As a result of healthy growth in protection and annuity business, VNB margins improved from 21.9% to 19.3% YoY
- AUM growth accelerated 23% YoY to ₹ 256870 crore
- Commission ratio increased ~20 bps YoY to 3.4% in Q3FY21 while opex ratio declined to 4.4% in Q3FY22. Consequently, total cost ratio declined by ~ 60 bps YoY to 7.8%
- Solvency ratio remained steady at healthy level of 2.09x

Q3FY22 earnings conference call highlights

- Individual rated new business premium were at ₹ 9070 crore with market share of 24.8% in 9MFY22 with improvement of 143 basis points over 9MFY21 while Individual new business premium was at ₹ 19790 crore with private market share of 23.7%
- New partnerships such as Indian Bank, Uco Bank, South Indian Bank, Yes Bank and Punjab Sind Bank registered growth of 48%. These relationships contribute almost 3% of the individual APE as on December 31, 2021
- Covid claims net of reinsurance paid as well as outstanding were at ₹ 1530 crore. The company has kept additional reserve amounting to ₹ 270 crore for Covid-19 pandemic over and above the policy liabilities
- Other channels like direct, corporate agents, brokers, online and web aggregators grew 69% in terms of individual new business premium and 50% in Individual APE. New business premium through other channel registered growth of 61%
- In annuity, individual annuity was at ₹ 1200 crore while group annuity was ₹ 1443 crore. Under group protection business, credit life was at ₹ 1140 crore while GTI was at ₹ 280 crore
- The management expects product mix at 12-15% in protection, 15-20% in non-par platina or similar products, annuities at 10% with remaining share that of Ulips
- Volume of business, product mix and pricing has helped in VNB margin expansion by 260 bps from 19.3% in 9MFY21 to 21.9% in 9MFY22

Peer comparison

Exhibit 1: Peer Comparison																
Santar / Company	CMP	CMP		M Cap EPS (₹)			P/E (x)		P/EV (x)			RoE (%)				
Sector / Company (₹)	TP(₹)	Rating	(₹ bn)	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	
SBI Life Insurance	1214	1400	Buy	1,238	28.5	13.4	14.2	42.6	90.9	85.3	6.4	5.5	4.6	42.5	16.0	15.2
HDFC Life	642	800	Buy	1354	3.6	3.9	4.1	176.6	163.0	156.5	18.3	14.5	12.5	32.8	32.7	28.5

Source: Company, ICICI Direct Research

We believe SBIL deserves premium valuation given diversified product mix, strong distribution and focus on improving persistency.

Exhibit	2:	Variance	Anal	vsis
		• an an o o	/	,010

	Q3FY22	Q3FY22E	Q3FY21	YoY (%)	02FY22	QoQ (%)	Comments
First Year Premium	4,073.6	4,105.7	3,276.5	24.3	3,609.7	12.8	ULIP and protection business contributed to premium growth
Renewal Premium	9,652.9	10,189.5	8,435.6	14.4	7,775.1	24.2	
Single Premium	4,429.4	4,316.8	2,162.3	104.8	3,333.8	32.9	
Net Premium income	18,025	17,770	13,766	30.9	14,661	23.0	
Income from Investments	2,424.1	6,271.1	12,776.9	-81.0	10,734.4	-77.4	Income from investment remained muted YoY
Total revenue	20,458.3	24,061	26,551.9	-22.9	25,404.1	-19.5	
Commission	614.6	675.3	517.2	18.8	529.9	16.0	Commission ratio remained steady at 3.4%
Operating expenses	787.6	888.5	645.3	22.0	747.6	5.4	
Management Expenses	1,402.1	1,563.7	1,162.5	20.6	1,277.5	9.8	Mgt expense ratio lower at 7.8%
Benefits paid	6,472.6	11,106.1	4,643.9	39.4	12,702.1	-49.0	Moderation in Covid claims
Change in Actuarial Liability	12,115.1	10,872.3	20,243.6	-40.2	10,978.1	10.4	
Total Expenses	20,222.2	23,788.8	26,255.4	-23.0	25,148.0	-19.6	
Surplus/ (deficit)	236.1	272.1	296.5	-20.4	256.1	-7.8	Higher benefit paid kept surplus lower
Transfer to SH's A/c	168.3	90.0	65.7	156.0	134.3	25.3	
Transfer to SH's A/c	168.3	90.0	65.7	156.0	134.3	25.3	
Investment income	222.5	224.6	174.5	27.5	240.6	-7.5	
Profit/ (loss) before tax	381.4	297.6	233.1	63.6	251.9	51.4	
PAT	364.1	276.8	232.9	56.3	246.6	47.6	Higher appropriation supports PAT
Key Metrics							
NBP	8,502.9	8,422.5	5,438.8	56.3	6,943.6	22.5	
AUM	256.870	250,844	209.500	22.6	244,180	5.2	
IEV*	35,290.0	NA	29,860.0	18.2	NA	NA	

Source: Company, ICICI Direct Research

		FY22E			FY23E		FY24E
(₹ Crore)	Old	New	% Change	Old	New	% Change	Introduced
Premiums earned - Net	57025	58,692	2.9	65,760.7	67890	3.2	78629
Total	86659	84,203	-2.8	87,359.0	93980	7.6	108430
Transfer to Shareholders' account	823	1,027	24.9	1,705.7	1340	-21.4	1859
PAT	1299	1,322	1.8	2,207.8	1647	-25.4	2181
EV	366	367	0.3	428.1	432	1.0	508

Source: Company, ICICI Direct Research

Exhibit 4: Assun	nption						
		Curre	ent			Earlier	
	FY21	FY22E	FY23E	FY24E	FY21	FY22E	FY23E
NBP growth	23.6	19.5	15.5	15.5	23.6	14.5	14.3
AUM growth	25.8	25.6	21.4	19.9	25.8	26.9	18.5
EV Growth	18.0	18.2	17.8	17.6	18.0	17.8	17.1
Comission ratio	3.2	3.5	3.5	3.5	3.2	3.5	3.5
VNB Margin	20.4	21.7	21.8	21.8	20.4	21.7	21.8
Conservation ratio	87.5	86.6	85.6	85.7	87.5	85.0	85.7
Opearating RoEV	16.9	17.3	17.7	18.1	16.9	17.3	17.7

Source: Company, ICICI Direct Research

Financial summary

Exhibit 5: Policyholders Account					
(₹ Crore)	FY20	FY21E	FY22E	FY23E	FY24E
Premiums earned - Net	40334.4	49769.2	58692.5	67889.6	78628.9
Income from Investments	2997.0	31456.0	24981.9	25594.1	29332.7
Other income	70.2	35.8	100.4	110.4	121.5
Contribution from the Shareholders' account	47.6	824.8	428.4	385.6	347.0
Total	43449.2	82084.9	84203.2	93979.7	108430.1
Commission	1477.8	1742.5	2049.1	2380.1	2767.6
Operating expenses	2592.0	2448.5	3606.9	4172.1	4832.1
Benefits paid (Net)	16215.0	21582.7	29924.5	30446.9	37102.7
Change in valuation of policy liabilities	20605.0	53934.2	46042.3	53676.5	59635.2
Others	7.9	-0.8	8.0	8.0	8.0
Provision for tax	1059.9	741.0	1474.9	1706.0	1975.9
Surplus/(deficit) after tax	1491.6	1807.4	1097.5	1590.1	2108.6
Transfer to Shareholders' account	1059.6	1678.8	1027.5	1340.1	1858.6

Source: Company, ICICI Direct Research

Exhibit 6: Shareholders Account					
(₹ Crore)	FY20	FY21E	FY22E	FY23E	FY24E
Amounts transferred from Policyholders' account	1059.6	1678.8	1027.5	1340.1	1858.6
Income from investments	490.7	694.8	923.6	894.8	875.6
Total	1550	2374	1951	2235	2734
Expenses other than insurance	70.0	31.0	168.0	151.2	136.1
Contribution to Policyholders' account	47.6	824.8	428.4	385.6	347.0
Others	15.9	-24.7	-24.7	-24.7	-24.7
Profit before Tax	1432.7	1542.5	1354.7	1698.2	2251.1
Provision for tax	-9.0	86.6	32.4	50.7	70.0
PAT	1441.7	1455.9	1322.3	1647.5	2181.0

Source: Company, ICICI Direct Research

Exhibit 7: Balance Sheet					
(₹ Crore)	FY20	FY21E	FY22E	FY23E	FY24E
Sources of Funds					
Share capital	1000	1000	1000	1000	1000
Reserve and surplus	8885	9093	9810	10906	12420
Credit/[debit] fair value change account	20	308	308	308	308
Networth	9905	10400	11118	12214	13728
Policyholders' funds	157733	200949	245539	299216	358851
Total Liabilities	168352	211349	258371	313643	375292
Applications of Funds					
Shareholders' investments	7924	8605	8664	8944	10080
Policyholders' investments	75159	93936	120203	148056	179570
Asset held to cover linked liabilities	76072	98215	122443	148121	176090
Loans	212	358	405	457	517
Fixed assets - net block	755	565	947	1061	1188
Net current assets	8229	9670	5421	6715	7559
Total Assets	168352	211349	258083	313356	375005

Source: Company, ICICI Direct Research

Exhibit 9. Koy Potion					
Exhibit 8: Key Ratios (Year-end March)	FY20	FY21	FY22E	FY23E	FY24E
Valuation	1120				11476
No. of Equity Shares (Crore)	100.0	100.0	100.0	100.0	100.0
Diluted EPS (₹)	14.2	14.6	8.9	14.0	19.3
DPS (₹)	2.6	2.5	1.6	2.5	3.5
BV (₹)	99.0	104.2	108.3	119.3	134.4
EV per share	263	310	367	432	508
P/E	86.9	85.0	138.6	88.5	64.1
P/BV	12.5	11.9	11.4	10.4	9.2
P/IEV	4.7	4.0	3.4	2.9	2.4
Efficiency Ratios (%)					
Commission expenses as a % of Gross Premium	3.6	3.2	3.5	3.5	3.5
Management expenses incl commission as a %	10.0	9.4	9.6	9.6	9.6
Return Ratios and capital (%)					
Return on Net worth	15.2	15.2	8.4	12.3	15.2
Opearating RoEV	17.5	16.9	17.3	17.7	18.1
Solvency Ratio	200	200	200	200	200
Key Ratios (%)					
Conservation Ratio	85.1	87.5	86.6	85.6	85.7
VNB Margin	18.7	20.4	21.7	21.8	21.8
Surrender Ratio	4.7	4.8	6.0	4.9	4.9
Benefits paid as a % of Opening Liability	11.7	11.9	14.9	12.3	12.3
NBP (proportion %)					

Source: Company, ICICI Direct Research

pankaj.pandey@icicisecurities.com

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15% Hold: -5% to 15%; Reduce: -15% to -5%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ICICI Securities | Retail Research

ANALYST CERTIFICATION

I/We, Kajal Gandhi, CA, Vishal Namolia, MBA. Sameer Sawant, MBA and Dixit Sankharva, MBA Research Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities cacepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.